Published December 15, 2022
- CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
- The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
- This review assesses atezolizumab (Tecentriq), 1,200 mg/mL and 840 mg/14 mL, IV infusion.
- Indication: As monotherapy for adjuvant treatment following complete resection and no progression after platinum-based adjuvant chemotherapy for adult patients with stage II to IIIA (according to AJCC/UICC 7th edition1) non-small cell lung cancer (NSCLC) whose tumours have PD-L1 expression on ≥ 50% of TCs.